In vitro potentiation of epirubicin activity by ionidamine in a human breast cancer cell line

D. Del Bufalo, G. Zupi

Research output: Contribution to journalArticlepeer-review

Abstract

The ability of lonidamine to modulate the lethal activity of epirubicin, an adriamycin analog, was evaluated in a human multidrug resistant breast cancer cell line (MCF7 ADM). Our data show that lonidamine induces a strong inhibition of DNA synthesis and impairment of mitochondrial activity in epirubicin-damaged cells, thus potentiating the antineoplastic activity of the adriamycin derivative. This study provides evidence that drug resistance could be modulated by lonidamine and indicates the potential usefulness of lonidamine in combination with epirubicin for the treatment of breast cancer patients.

Original languageEnglish
Pages (from-to)737-740
Number of pages4
JournalInternational Journal of Oncology
Volume4
Issue numberSUPPL.
Publication statusPublished - 1994

Keywords

  • breast cancer
  • epirubicin
  • lonidamine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'In vitro potentiation of epirubicin activity by ionidamine in a human breast cancer cell line'. Together they form a unique fingerprint.

Cite this